Compositions and methods for the treatment of macular degeneration

Patent metadata

Field	Value
Publication number	US-9814701-B2
Application number	US-201013514769-A
Country	US
Kind code	B2
Filing date	Dec 9, 2010
Priority date	Dec 11, 2009
Publication date	Nov 14, 2017
Grant date	Nov 14, 2017

Abstract

The present invention is directed to topical ophthalmic compositions of a lipophilic compound and an oligomeric or polymeric carrier wherein the compositions are useful in the treatment and prevention of macular degeneration. The invention also includes methods of treating macular degeneration by using a topical ophthalmic composition of a lipophilic compound and an oligomeric or polymeric carrier.

First claim

What is claimed is:

1. An ophthalmic composition comprising a compound of the following formula:

or a pharmaceutically acceptable salt thereof;
β-cyclodextrin sulfobutylether or a pharmaceutically acceptable salt thereof; and
an ophthalmically acceptable excipient;
wherein the compound is present at a concentration of about 0.05% w/v and wherein the ophthalmic composition comprises an aqueous solution.

2. The composition of claim 1 , wherein the β-cyclodextrin sulfobutylether is the sodium salt of β-cyclodextrin sulfobutylether.

3. The composition of claim 1 , wherein the aqueous solution is at a pH of 6.5-7.5.

4. The composition of claim 1 , wherein the β-cyclodextrin sulfobutylether or pharmaceutically acceptable salt thereof is at a concentration of about 9.5-20% w/v.

5. The composition of claim 1 , wherein β-cyclodextrin sulfobutylether or pharmaceutically acceptable salt thereof is at a concentration of about 9.5% w/v.

6. The composition of claim 1 , wherein the β-cyclodextrin sulfobutylether or pharmaceutically acceptable salt thereof is at a concentration of about 0.01-30% w/v.

7. The composition of claim 1 , wherein the β-cyclodextrin sulfobutylether or pharmaceutically acceptable salt thereof is at about 5-25% w/v.

8. The composition of claim 1 , wherein the β-cyclodextrin sulfobutylether or pharmaceutically acceptable salt thereof is at about 2% w/v.

9. The composition of claim 1 , wherein the ophthalmically acceptable excipient comprises a buffer.

10. The composition of claim 9 , wherein the buffer comprises a phosphate buffer.

Assignees

• Jordan Thomas A
• Chabala John Clifford
• Cagle Gerald D
• Aldeyra Therapeutics Inc

Inventors

• Jordan Thomas A
• Chabala John Clifford
• Cagle Gerald D

Classifications

• A61K31/47

  Quinolines; Isoquinolines · CPC title

• A61K9/0048

  Eye, e.g. artificial tears · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61K47/40

  Cyclodextrins; Derivatives thereof · CPC title

• A61K31/423 Primary

  condensed with carbocyclic rings · CPC title